Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights Our Pancreatic Cancer Analysis: How We Did It

Our Pancreatic Cancer Analysis: How We Did It

  • June 1, 2017
  • Posted in Disease Awareness

This post was last updated on December 2, 2019 at 9:51 pm

The Prognos Study Method

By Carol Smyth, MD & Brian Saindon

Background

About 80% of pancreatic cancers are found late, due to the lack of symptoms associated with the tumor until its late stages. Finding the tumor late results in poor survival rates. There is currently no specific blood test to screen for pancreatic cancer, and researchers around the world are working on identifying tests that would help to identify early pancreatic tumors. A 2009 study by Harsha et al found that over 1,000 genes can be overexpressed in pancreatic cancer, implying that there are many potential biomarkers waiting to be discovered (http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000046).

Method

Using the Prognos database of lab tests, which currently includes 9 billion tests from over 160 million patients, we identified patients at first diagnosis of pancreatic cancer via ICD-9 and ICD-10 codes in 2016. Tracking their lab results retrospectively, we looked back by 5 years to determine if there was a pattern in the “noise” of the lab tests, to see if there are potentially abnormal results in commonly conducted lab tests that may indicate an increased risk of pancreatic cancer on a population basis. This type of retrospective analysis has not been published to date in pancreatic cancer, to the best of our knowledge/research. Because there are many tests that were candidates for this analysis, we elected to focus on the following lab tests and results:

  • CA 19-9 and alkaline phosphatase because our previous research suggested that these were potential biomarkers (see http://abstracts.asco.org/156/AbstView_156_153453.html). In addition, CA 19-9 is the only biomarker approved by the FDA for pancreatic cancer (http://www.sciencedirect.com/science/article/pii/S1590865815006908).
  • Amylase – levels found to be high in less than 50% of patients with operable pancreatic cancer tumors (http://emedicine.medscape.com/article/280605-overview)
  • HbA1c and fasting glucose – due to the high rate of diabetes in patients with pancreatic cancer –  new onset diabetes is common in the year prior to diagnosis of pancreatic cancer
  • CA 125 – we included this test because previous studies suggest a rise in CA 125 is present up to 2 years prior to pancreatic cancer diagnosis (https://www.pancreaticcancer.org.uk/latest-news/2015/february/tumour-biomarkers-research-shows-promise-for-early-detection/)
  • Hemoglobin and platelets – these test results are often low in patients with pancreatic cancer

In the Prognos database, we identified 11,571 patients identified with ICD codes for pancreatic cancer in the calendar year 2016. Demographics of this patient group follow. We note that the group is approximately equal between genders, and that the majority of patients (>60%) are between the ages of 61 and 80 years old. These findings are in keeping with data published by the National Institutes of Health (https://seer.cancer.gov/statfacts/html/pancreas.html).

Cohort Descriptives

MeasureFrequency (n)(%)
Patient Gender
Male5,67249.02%
Female5,89850.97%
Unknown10.01%
Patient Age Distribution
Patient Age Group (years)
0-10100.09%
11-20110.10%
21-30450.39%
31-401701.47%
41-505294.57%
51-60201417.41%
61-70381432.96%
71-80329628.49%
81-90149712.94%
91-1001821.57%
>10020.02%
Unknown10.01%
Screen Shot 2017-06-01 at 3.35.33 PM

Patients with First Pancreatic Cancer Diagnosis in 2016 (n=11,571)

In the next blog, we will report on the analysis of our retrospective look at the common lab tests listed above, to see if there is a pattern in abnormal lab results over the 5-year period prior to diagnosis of pancreatic cancer in the 2016 patient cohort. Our hope is that identification of a pattern, if any, might lead to identification of a panel of common tests that might be used for screening for this lethal tumor.

Reading List:

  • http://emedicine.medscape.com/article/280605-overview
  • http://www.sciencedirect.com/science/article/pii/S1590865815006908
« Continuing the Search for Pancreatic Cancer Screening Tests
Pancreatic Cancer Screening: Initial Results »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.